UBX - Unity Biotechnology GAAP EPS of -$0.19 beats by $0.10 revenue of $0.24M
- Unity Biotechnology press release ( NASDAQ: UBX ): Q2 GAAP EPS of -$0.19 beats by $0.10 .
- Revenue of $0.24M.
- Cash, cash equivalents and marketable securities totaled $64.5 million as of June 30, 2022, compared with $79.2 million as of March 31, 2022.
- UNITY believes that current cash, cash equivalents, and marketable securities are sufficient to fund operations through the first quarter of 2023.
- Shares +96% PM.
For further details see:
Unity Biotechnology GAAP EPS of -$0.19 beats by $0.10, revenue of $0.24M